US court rules on Helsinn Healthcare vs Teva on Aloxi patent

2 May 2017
medical_legal_law_big

A panel of the US Court of Appeals for the Federal Circuit yesterday reversed the opinion of the District Court for the District of New Jersey and ruled that certain patent claims covering Aloxi (palonosetron hydrochloride) injection are not valid and are not infringed by Teva Pharmaceutical Industries’ (NYSE: TEVA) generic palonosetron product, says privately-held Swiss drugmaker Helsinn Healthcare.

This means that Israeli generics giant Teva will not be able to launch a generic version of Aloxi until additional steps are taken by the Federal Circuit, the New Jersey Court and the Food and Drug Administration allowing such a launch. This process may take several months, and potentially longer if the Federal Circuit were to grant a petition for review.

Helsinn and partner Eisai (TYO: 4523) say they are disappointed with the court’s ruling. Protecting intellectual property is vital to a company’s ability to continue developing medicines that will make a difference in the lives of patients. Helsinn and Eisai maintain their position that the patents protecting Aloxi are valid and will pursue further legal options to protect and enforce such patents.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical